Clinical data | |
---|---|
Trade names | Izervay |
Other names | Zimura |
License data | |
Routes of administration | Intravitreal |
Drug class | Complement inhibitor |
ATC code | |
Legal status | |
Legal status | |
Identifiers | |
CAS Number | |
DrugBank | |
UNII | |
KEGG | |
Chemical and physical data | |
Formula | C395H453F21N142Na39O262P39 |
Molar mass | 13885.245 g·mol−1 |
Avacincaptad pegol, sold under the brand name Izervay, is a medication used for the treatment of age-related macular degeneration. [1] Avacincaptad pegol is a complement inhibitor. [1]
Avacincaptad pegol was approved for medical use in the United States in August 2023. [2] [3] [4]
Avacincaptad pegol is indicated for the treatment of geographic atrophy secondary to age-related macular degeneration. [5]
Avacincaptad pegol is the international nonproprietary name. [6]